Improving immune cell function in cystic fibrosis with new medications
Resue of CF phagocyte function with CFTR modulator therapy
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11059895
This study is looking at a new treatment for cystic fibrosis to see how it helps immune cells fight off infections better, which could lead to more personalized care for patients who still struggle with chronic infections.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11059895 on ClinicalTrials.gov |
What this research studies
This research investigates how a new combination therapy for cystic fibrosis (CF) affects the function of immune cells that are crucial for fighting bacterial infections. The study aims to understand why patients with CF still experience chronic infections despite advancements in treatment. By examining the effects of highly effective CFTR modulator therapy on macrophages and neutrophils, the research will explore how these immune cells can be restored to better combat infections. The findings could lead to personalized treatment strategies based on individual responses to therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis who are undergoing treatment with CFTR modulator therapy.
Not a fit: Patients without cystic fibrosis or those not receiving CFTR modulator therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance the ability of patients with cystic fibrosis to clear bacterial infections, potentially improving their overall health and quality of life.
How similar studies have performed: Previous research has shown promising results in improving immune function in cystic fibrosis patients using similar therapeutic approaches.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOPP, BENJAMIN T — EMORY UNIVERSITY
- Study coordinator: KOPP, BENJAMIN T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.